Alnylam Pharmaceuticals (ALNY) Leases (2011 - 2026)

Alnylam Pharmaceuticals (ALNY) has 16 years of Leases data on file, last reported at $189.3 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 4.02% year-over-year to $189.3 million; the trailing twelve-month figure through Mar 2026 stood at $189.3 million (down 4.02% YoY), and the FY2025 full-year result was $194.9 million, up 1.97% from the prior year.
• Leases for Q1 2026 stood at $189.3 million, down from $194.9 million in the prior quarter.
• Across five years, Leases topped out at $228.8 million in Q1 2022 and bottomed at $189.3 million in Q1 2026.
• The 5-year median for Leases is $198.3 million (2024), against an average of $203.5 million.
• The widest annual swing landed in 2024, when Leases slipped 9.11%; it then advanced 1.97% in 2025.
• A 5-year view of Leases shows it stood at $215.1 million in 2022, then fell by 7.16% to $199.7 million in 2023, then retreated by 4.3% to $191.1 million in 2024, then rose by 1.97% to $194.9 million in 2025, then slipped by 2.88% to $189.3 million in 2026.
• The last three Leases figures came in at $189.3 million (Q1 2026), $194.9 million (Q4 2025), and $191.4 million (Q3 2025), per Business Quant data.

Peer Comparison